Big Move For Hepion Pharmaceuticals, Inc.

Tue, Jan 28, 2025 at 07:25 PM

Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ) rocketted at $0.22, representing a gain of 35%. The stock appeared on our News Catalysts scanner on Wed, Jan 22, 2025 at 10:30 AM in the 'PUBLIC OFFERING' category. From Tue, Jan 14, 2025, the stock recorded 44.44% Up Days and 40.00% Green Days

About Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ)

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

Top 10 Gainers:

F45 Training Holdings Inc. (FXLV:NYSE), 269.23%
Dunxin Financial Holdings Limited (DXF:NYSEMKT), 168.26%
Biomotion Sciences (SLXN:NASDAQ), 132.76%
Trinity Biotech plc (TRIB:NASDAQ), 78.95%
Planet Image International Limited (YIBO:NASDAQ), 66.88%
Diginex Limited (DGNX:NASDAQ), 59.13%
IMAC Holdings Inc. (BACK:NASDAQ), 47.17%
TransCode Therapeutics Inc. (RNAZ:NASDAQ), 45.53%
LatAmGrowth SPAC (LATG:NASDAQ), 40%
Hepion Pharmaceuticals, Inc. (HEPA:NASDAQ), 34.97%